{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:09:35Z","timestamp":1774069775312,"version":"3.50.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI143567"],"award-info":[{"award-number":["R01AI143567"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["RD16CIII\/0002\/0001"],"award-info":[{"award-number":["RD16CIII\/0002\/0001"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["SAF2016-78480-R"],"award-info":[{"award-number":["SAF2016-78480-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["FIS PI16CIII\/00034-ISCIII-FEDER"],"award-info":[{"award-number":["FIS PI16CIII\/00034-ISCIII-FEDER"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.bcp.2020.114203","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T02:32:01Z","timestamp":1597890721000},"page":"114203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection"],"prefix":"10.1016","volume":"182","author":[{"given":"Lorena","family":"Vig\u00f3n","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Rodr\u00edguez-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Luna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Sandon\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiomar","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Luis","family":"Steegmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Climent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Plana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"P\u00e9rez-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"de Ory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Alcam\u00ed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Planelles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Rosa","family":"L\u00f3pez-Huertas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayte","family":"Coiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.114203_b0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/nature13594","article-title":"Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys","volume":"512","author":"Whitney","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114203_b0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2020.114203_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002417","article-title":"HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study","volume":"14","author":"Henrich","year":"2017","journal-title":"PLoS Med."},{"key":"10.1016\/j.bcp.2020.114203_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002288","article-title":"Homeostatic proliferation fails to efficiently reactivate HIV-1 latently infected central memory CD4+ T cells","volume":"7","author":"Bosque","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114203_b0025","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1084\/jem.20170193","article-title":"Proliferation of latently infected CD4 + T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics","volume":"214","author":"Hosmane","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2020.114203_b0030","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/487439a","article-title":"HIV: shock and kill","volume":"487","author":"Deeks","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2020.114203_b0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007991","article-title":"Latency reversal agents affect differently the latent reservoir present in distinct CD4+ t subpopulations","author":"Grau-Exp\u00f3sito","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.bcp.2020.114203_b0040","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000001645","article-title":"Natural killer cells in HIV-1 infection and therapy","author":"Mikulak","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.bcp.2020.114203_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210540","article-title":"An altered cytotoxic program of CD8 + T-cells in HIV-infected patients despite HAART-induced viral suppression","author":"Perdomo-Celis","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2020.114203_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.tim.2015.11.003","article-title":"Reversal of latency as part of a cure for HIV-1","author":"Rasmussen","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.bcp.2020.114203_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113625","article-title":"Dasatinib protects humanized mice from acute HIV-1 infection","volume":"174","author":"Salgado","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114203_b0060","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.celrep.2016.02.022","article-title":"IL-7 induces SAMHD1 phosphorylation in CD4+ T lymphocytes, improving early steps of HIV-1 life cycle","volume":"14","author":"Coiras","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2020.114203_b0065","doi-asserted-by":"crossref","unstructured":"M. Bermejo, J. Ambrosioni, G. Bautista, N. Climent, E. Mateos, C. Rovira, S. Rodr\u00edguez-Mora, M.R. L\u00f3pez-Huertas, V. Garc\u00eda-Guti\u00e9rrez, J.L. Steegmann, R. Duarte, F. Cervantes, M. Plana, J.M. Mir\u00f3, J. Alcam\u00ed, M. Coiras, C.M. Bermejo M, Ambrosioni J, Bautista G, Climent N, Mateos E, Rovira C, Rodr\u00edguez-Mora S, L\u00f3pez-Huertas MR, Garc\u00eda-Guti\u00e9rrez V, Steegmann JL, Duarte R, Cervantes F, Plana M, Mir\u00f3 JM, Alcam\u00ed J, Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors, Biochem. Pharmacol. 156 (2018) 248\u2013264. doi: 10.1016\/j.bcp.2018.08.031.","DOI":"10.1016\/j.bcp.2018.08.031"},{"key":"10.1016\/j.bcp.2020.114203_b0070","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.139337","article-title":"Chronic myeloid leukemia: Reminiscences and dreams","author":"Mughal","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.bcp.2020.114203_b0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcp.2016.02.002","article-title":"Dasatinib inhibits HIV-1 replication through the interference of SAMHD1 phosphorylation in CD4+ T cells","volume":"106","author":"Bermejo","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114203_b0080","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00819-18","article-title":"SAMHD1 phosphorylation coordinates the Anti-HIV-1 response by diverse Interferons and Tyrosine Kinase Inhibition","author":"Szaniawski","year":"2018","journal-title":"MBio."},{"key":"10.1016\/j.bcp.2020.114203_b0085","doi-asserted-by":"crossref","unstructured":"H. Lahouassa, W. Daddacha, H. Hofmann, D. Ayinde, E.C. Logue, L. Dragin, N. Bloch, C. Maudet, M. Bertrand, T. Gramberg, G. Pancino, S. Priet, B. Canard, N. Laguette, M. Benkirane, C. Transy, N.R. Landau, B. Kim, F. Margottin-Goguet, SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates, Nat. Immunol. 13 (2012) 223\u2013228. doi: 10.1038\/ni.2236.","DOI":"10.1038\/ni.2236"},{"key":"10.1016\/j.bcp.2020.114203_b0090","doi-asserted-by":"crossref","unstructured":"A. Cribier, B. Descours, A.L.C. Valad??o, N. Laguette, M. Benkirane, Phosphorylation of SAMHD1 by Cyclin A2\/CDK1 Regulates Its Restriction Activity toward HIV-1, Cell Rep. 3 (2013) 1036\u20131043. doi: 10.1016\/j.celrep.2013.03.017.","DOI":"10.1016\/j.celrep.2013.03.017"},{"key":"10.1016\/j.bcp.2020.114203_b0095","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","article-title":"Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy","volume":"116","author":"Kreutzman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2020.114203_b0100","doi-asserted-by":"crossref","DOI":"10.3109\/10428194.2011.647017","article-title":"Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib","author":"Hayashi","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.bcp.2020.114203_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2012.348","article-title":"Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2020.114203_b0110","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.29933","article-title":"Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity","author":"Schiffer","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2020.114203_b0115","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","author":"Cannon","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.bcp.2020.114203_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2015.02.008","article-title":"Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function","author":"Schlums","year":"2015","journal-title":"Immunity."},{"key":"10.1016\/j.bcp.2020.114203_b0125","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-016-1803-z","article-title":"CD57 in human natural killer cells and T-lymphocytes","author":"Kared","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2020.114203_b0130","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.21377","article-title":"Cytomegalovirus pulls strings behind NK cells","author":"Kadowaki","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.114203_b0135","article-title":"CD56+CD57+ infiltrates as the most predominant subset of intragraft natural killer cells in renal transplant biopsies with antibody-mediated rejection","author":"Jung","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2020.114203_b0140","article-title":"Increased frequency of TCR\u03b3\u03b4+ T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia","author":"Lamb","year":"1996","journal-title":"J. Hematotherapy Stem Cell Res."},{"key":"10.1016\/j.bcp.2020.114203_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00761","article-title":"Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications","author":"Lawand","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2020.114203_b0150","doi-asserted-by":"crossref","DOI":"10.1080\/08820139.2018.1529039","article-title":"Antigen-presenting cell characteristics of human \u03b3\u03b4 T lymphocytes in chronic myeloid leukemia","author":"Sawaisorn","year":"2019","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.bcp.2020.114203_b0155","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1128\/jvi.59.2.284-291.1986","article-title":"Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone","volume":"59","author":"Adachi","year":"1986","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2020.114203_b0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jmv.20770","article-title":"A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1","volume":"79","author":"Garcia-Perez","year":"2007","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.bcp.2020.114203_b0165","doi-asserted-by":"crossref","first-page":"10119","DOI":"10.1128\/JVI.77.18.10119-10124.2003","article-title":"Analysis of Early Human Immunodeficiency Virus Type 1 DNA Synthesis by Use of a New Sensitive Assay for Quantifying Integrated Provirus","volume":"77","author":"Brussel","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2020.114203_b0170","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1128\/JVI.80.8.3712-3720.2006","article-title":"Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex","volume":"80","author":"Dismuke","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2020.114203_b0175","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-04-3804","article-title":"Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells","author":"Gastpar","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.114203_b0180","doi-asserted-by":"crossref","DOI":"10.1172\/JCI97555","article-title":"Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ t cells","author":"Huang","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.114203_b0185","article-title":"Strategies for the cure of HIV infection","author":"Rodr\u00edguez-Mu\u00f1oz","year":"2019","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"10.1016\/j.bcp.2020.114203_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2011.135","article-title":"Expansion of highly differentiated CD8 T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation","author":"Kreutzman","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2020.114203_b0195","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR\u2013ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.bcp.2020.114203_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113625","article-title":"Dasatinib protects humanized mice from acute HIV-1 infection","author":"Salgado","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2020.114203_b0205","article-title":"Development and dynamics of robust T-cell responses to CML under imatinib treatment","author":"Chen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2020.114203_b0210","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.27537","article-title":"Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinib","author":"Hassold","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2020.114203_b0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.03152","article-title":"NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia","author":"Chang","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bcp.2020.114203_b0220","doi-asserted-by":"crossref","DOI":"10.1182\/asheducation.V2012.1.122.3798214","article-title":"Is going for cure in chronic myeloid leukemia possible and justifiable?","author":"Mahon","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.bcp.2020.114203_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bcp.2020.114203_b0230","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.021","article-title":"Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase","author":"Breccia","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.bcp.2020.114203_b0235","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3109\/10428194.2012.656626","article-title":"Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications","volume":"53","author":"Rodriguez","year":"2012","journal-title":"Leuk. Lymphoma."},{"key":"10.1016\/j.bcp.2020.114203_b0240","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4137\/BMI.S22430","article-title":"Risk of infectious complications in hemato-oncological patients treated with kinase inhibitors","volume":"10s3","author":"Reinwald","year":"2015","journal-title":"Biomark. Insights"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220304391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220304391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:10:38Z","timestamp":1762096238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220304391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":48,"alternative-id":["S0006295220304391"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114203","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114203","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"114203"}}